News | Radiopharmaceuticals and Tracers | March 08, 2017

Cardinal Health to license a portion back to Navidea for development and sale of new products in North America, production and sale of Lymphoseek outside North America

Navidea, Lymphoseek, North American rights, sale, Cardinal Health

March 8, 2017 — Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to Cardinal Health. Navidea received approximately $83 million at closing, and will have the opportunity to earn up to $227 million of contingent consideration based on certain milestones through 2026, with $17.1 million of that amount guaranteed over the next three years.

Lymphoseek is a radiopharmaceutical agent designed for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America. Cardinal Health will license a portion of the acquired intellectual property back to Navidea to allow Navidea to develop and sell new immunodiagnostic and immunotherapeutic products for specific purposes in North America, and to continue to produce and sell Lymphoseek, mostly under a different brand name, outside of North America.

As a result of this transaction, CRG has provided a full release of all liens on Navidea’s assets, and all frozen accounts will be transferred back to Navidea control. The unsecured loan from Platinum Partners has been also been repaid.

Post-closing and post-paying off all outstanding notes and transaction-related expenses, Navidea will have $15.6 million in cash and $3.3 million in payables, a large portion of which is tied to the 4694 program which Navidea is seeking to divest in the near term now that the liens have been released.

For more information: www.navidea.com, www.cardinalhealth.com

Related Content

News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
News | Molecular Imaging

October 29, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time October 29, 2021
arrow
News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
News | PET Imaging

October 18, 2021 — PSMA (prostate-specific membrane antigen) PET/CT is more accurate than conventional CT in the ...

Time October 18, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
Subscribe Now